Auvelity was Axsome Therapeutics’s largest revenue line in fiscal 2025, bringing in $507.09M of $638.50M (79%).
| Counterparty Name | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Auvelity | $5.17M | $130.07M | $291.38M | $507.09M |
| Sunosi | $44.87M | $140.53M | $94.32M | $124.79M |
| Symbravo | — | — | — | $6.61M |
| Total | $50.04M | $270.60M | $385.69M | $638.50M |
Axsome Therapeutics brought in $638.50M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Axsome Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $385.69M. Auvelity was the largest at $507.09M (79.4%), ahead of Sunosi at $124.79M (19.5%) and Symbravo at $6.61M (1.0%).
Compared with fiscal 2024, Auvelity grew 74.0% to $507.09M and Sunosi grew 32.3% to $124.79M.
Axsome Therapeutics began breaking out Symbravo in fiscal 2025, when it brought in $6.61M.
Product Sales was Axsome Therapeutics’s largest product and service line in fiscal 2025, bringing in $633.80M of $638.50M (99%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Product Sales | $50.04M | $202.46M | $381.68M | $633.80M |
| License Fee | — | $65.74M | — | — |
| Royalty & Milestone Revenue | — | $2.41M | $4.02M | $4.70M |
| Total | $50.04M | $270.60M | $385.69M | $638.50M |
Axsome Therapeutics brought in $638.50M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 65.5% from $385.69M in fiscal 2024. Product Sales was the largest at $633.80M (99.3%), ahead of Royalty & Milestone Revenue at $4.70M (0.7%).
Axsome Therapeutics began breaking out Royalty & Milestone Revenue in fiscal 2023, when it brought in $2.41M. Axsome Therapeutics stopped reporting License Fee as a separate line after fiscal 2023, when it brought in $65.74M.
United States was Axsome Therapeutics’s largest region in fiscal 2025, bringing in $628.62M of $638.50M (98%).
| Geography | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| United States | $49.13M | $197.22M | $378.16M | $628.62M |
| Ex-U.S. Markets | $905.00K | $73.38M | $7.53M | $9.88M |
| Total | $50.04M | $270.60M | $385.69M | $638.50M |
Axsome Therapeutics brought in $638.50M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 65.5% from $385.69M in fiscal 2024. United States was the largest at $628.62M (98.5%), ahead of Ex-U.S. Markets at $9.88M (1.5%).
From fiscal 2022 to 2025, combined revenue from these regions grew from $50.04M to $638.50M, a compound annual growth rate of 133.7%. United States' share held steady at about 98.5%.
Axsome Therapeutics (AXSM) reports its revenue by counterparty name, by product and service and by geography. In fiscal 2025, Auvelity was its largest revenue line, bringing in $507.09M (79.4% of the total), followed by Sunosi at $124.79M (19.5%).
Auvelity was Axsome Therapeutics' largest revenue line in fiscal 2025, bringing in $507.09M, or 79.4% of the $638.50M total across its three revenue lines.
Product Sales was Axsome Therapeutics' largest product and service line in fiscal 2025, bringing in $633.80M, or 99.3% of the $638.50M total across its two product and service lines.
United States was Axsome Therapeutics' largest region in fiscal 2025, bringing in $628.62M, or 98.5% of the $638.50M total across its two regions.
Every figure comes from Axsome Therapeutics' annual financial filings, as reported. Each line keeps the name Axsome Therapeutics gives it, and years follow its fiscal calendar.
Axsome Therapeutics' revenue by counterparty name goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.